Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06441591
PHASE2/PHASE3

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.

Official title: The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2024-07-10

Completion Date

2025-06-01

Last Updated

2024-07-11

Healthy Volunteers

No

Interventions

DRUG

Vinpocetine

Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel

DRUG

Standard Therapy

Anti-hypertensive and anti-diabetic medications according to the the institution's protocol

OTHER

Placebo

Starch-filled capsules, matching those of the intervention

Locations (2)

Ain Shams University Hospital

Cairo, Abbasseia, Egypt

Ain Shams Hospitals

Cairo, Abbasseya, Egypt